To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
About This Bill
Committee
Latest Action · May 15, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Next GEN Act of 2026 modifies Medicare's Drug Price Negotiation Program by changing how certain specialty drugs called engineered cyclic peptides are treated. These are drugs made from amino acids with specific chemical structures, developed using advanced screening methods, and designed to be taken by mouth, inhaled, or self-administered by patients. The bill extends the period these drugs are protected from price negotiation from 7 years to 11 years after FDA approval, giving manufacturers a longer window before Medicare can negotiate their prices. This change affects Medicare beneficiaries and taxpayers by potentially delaying lower drug prices for this category of medications, while benefiting pharmaceutical companies that develop these drugs. The changes take effect immediately upon enactment for any drug price lists published by Medicare after the bill becomes law.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.